Biogen (NASDAQ:BIIB) Price Target Raised to $272.00

Posted by Geri Gentry on Nov 1st, 2026

Biogen (NASDAQ:BIIB – Free Report) had its price target boosted by Canaccord Genuity Group from $248.00 to $272.00 in a research report report published on Thursday,Benzinga reports. They currently have a buy rating on the biotechnology company’s stock.

Several other brokerages also recently commented on BIIB. Wolfe Research raised Biogen from a “peer perform” rating to an “outperform” rating and set a $300.00 price objective for the company in a research note on Thursday, August 13th. Jefferies Financial Group reaffirmed a “buy” rating on shares of Biogen in a research report on Monday, July 13th. UBS Group lifted their target price on Biogen from $270.00 to $300.00 and gave the company a “buy” rating in a research report on Thursday. Wells Fargo & Company upped their price target on Biogen from $250.00 to $310.00 and gave the stock an “overweight” rating in a report on Tuesday, October 20th. Finally, Stifel Nicolaus set a $242.00 price target on Biogen in a research report on Thursday, September 10th. One investment analyst has rated the stock with a Strong Buy rating, twenty-one have given a Buy rating, ten have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $251.00.

View Our Latest Stock Analysis on BIIB

Biogen Trading Up 1.6%

BIIB opened at $253.62 on Thursday. The company has a debt-to-equity ratio of 0.39, a current ratio of 1.95 and a quick ratio of 1.26. Biogen has a fifty-two week low of $146.52 and a fifty-two week high of $258.78. The firm has a market capitalization of $37.49 billion, a PE ratio of 108.38, a P/E/G ratio of 2.97 and a beta of 0.09. The company’s 50-day moving average is $227.08 and its 200 day moving average is $201.04.

Biogen (NASDAQ:BIIB – Get Free Report) last announced its quarterly earnings results on Wednesday, October 28th. The biotechnology company reported $2.62 earnings per share for the quarter, beating the consensus estimate of $1.99 by $0.63. The business had revenue of $2.80 billion for the quarter, compared to analysts’ expectations of $2.63 billion. Biogen had a net margin of 3.37% and a return on equity of 9.38%. The firm’s revenue for the quarter was up 10.6% compared to the same quarter last year. During the same quarter last year, the firm earned $4.81 EPS. As a group, research analysts predict that Biogen will post 12.44 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Biogen

Institutional investors and hedge funds have recently bought and sold shares of the company. Bell Investment Advisors Inc purchased a new position in shares of Biogen during the 2nd quarter valued at $27,000. Align Financial LLC grew its stake in shares of Biogen by 339.3% during the 3rd quarter. Align Financial LLC now owns 123 shares of the biotechnology company’s stock worth $28,000 after acquiring an additional 95 shares during the period. Provenance Wealth Advisors LLC purchased a new stake in Biogen in the 3rd quarter worth about $29,000. Canton Hathaway LLC purchased a new stake in Biogen in the 3rd quarter worth about $31,000. Finally, Ashurst Perkins Coie Trust Co increased its holdings in Biogen by 92.2% in the 3rd quarter. Ashurst Perkins Coie Trust Co now owns 173 shares of the biotechnology company’s stock worth $39,000 after acquiring an additional 83 shares during the last quarter. 87.93% of the stock is owned by institutional investors.

Key Stories Impacting Biogen

Here are the key news stories impacting Biogen this week:

Positive Sentiment: Better-than-expected Q3 results: Biogen reported adjusted earnings of $2.62 per share, above the $1.99 consensus estimate, while revenue reached $2.80 billion versus expectations of $2.63 billion. Revenue increased 10.6% year over year, supporting the view that the company is returning to growth. Biogen Reaches New 1-Year High on Better-Than-Expected Earnings
Positive Sentiment: Analysts raised targets following the earnings beat: UBS lifted its target to $300, while Baird and Needham raised theirs to $290. Argus upgraded Biogen from “hold” to “buy” with a $280 target; RBC increased its target to $272 and retained an outperform rating. Canaccord Genuity also raised its target to $272 and assigned a buy rating. Analysts Increase Their Forecasts on Biogen After Upbeat Q3 Results
Positive Sentiment: Growth narrative is improving: RBC analysts said Biogen’s quarterly performance suggests a growth-led comeback, potentially sustaining investor momentum after a period of declining results. Biogen Swings Back to Growth as Stock Momentum Could Continue
Positive Sentiment: Alzheimer’s pipeline catalyst: Biogen plans to present long-term and real-world data at the November CTAD conference, including five-year Clarity AD extension data for lecanemab and additional Phase 2 CELIA data for diranersen. Positive results could strengthen confidence in the company’s Alzheimer’s portfolio and future growth prospects. Biogen to Present New Data Across Alzheimer’s Disease Portfolio at CTAD 2026
Neutral Sentiment: Mixed analyst valuation signals: TD Cowen and Truist raised targets to $260, but those imply only modest upside from the current level. The concentration of target increases after earnings is supportive, although expectations are now higher.
Negative Sentiment: Morgan Stanley remains cautious: The firm raised its target to $238 but kept an “equal weight” rating, indicating potential downside if Biogen’s growth recovery or pipeline data disappoints.

Biogen Company Profile

(Get Free Report)

Biogen Inc is a biotechnology company that discovers, develops and commercializes therapies for neurological and neurodegenerative diseases. Its areas of focus include multiple sclerosis, Alzheimer’s disease, spinal muscular atrophy, amyotrophic lateral sclerosis and other serious medical conditions.

The company’s portfolio includes multiple sclerosis treatments such as Tecfidera, Vumerity, Tysabri, Plegridy and Avonex, as well as Spinraza for spinal muscular atrophy. Biogen also markets Leqembi, an Alzheimer’s disease treatment developed in collaboration with Eisai, and works with partners to advance additional therapies and biosimilars.

Biogen was founded in 1978 and is headquartered in Cambridge, Massachusetts.